RSV Prefusion F Vaccine Effective in Preventing Hospitalization in Older Adults

Background: Respiratory syncytial virus (RSV) causes significant morbidity and mortality, especially in older adults and those with other health conditions. A recently developed vaccine containing prefusion F glycoproteins from the virus (RSVpreF) has been shown to decrease RSV-related lower respiratory tract disease, but studies have been insufficient to comment on the effect of hospitalizations. Design: Phase 4, investigator-initiated, pragmatic, open-label, parallel-group, individually randomized clinical trial. Participants: 131,276 adults aged ≥60 years in Denmark without contraindication to vaccine. Methods: Patients were randomized 1:1 to receive the RSVpreF vaccine (the RSVpreF group) or no vaccine (the control group). Participants were then monitored on the Danish Health Data Authority with primary end point of hospitalization for RSV-related respiratory tract disease, and secondary end points of hospitalization for RSV-related lower respiratory tract disease specifically more...